摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-(4-(hydroxymethyl)phenyl)-9-phenyl-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one | 1207453-48-2

中文名称
——
中文别名
——
英文名称
8-(4-(hydroxymethyl)phenyl)-9-phenyl-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one
英文别名
11-[4-(hydroxymethyl)phenyl]-12-phenyl-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
8-(4-(hydroxymethyl)phenyl)-9-phenyl-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one化学式
CAS
1207453-48-2
化学式
C23H19N3O2
mdl
——
分子量
369.423
InChiKey
WQCHPMOBAQVOCU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    28
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    73.7
  • 氢给体数:
    3
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
    申请人:Wang Bing
    公开号:US20100035883A1
    公开(公告)日:2010-02-11
    A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
    具有以下结构的化合物:其中取代基Y、Z、A、B、R1、R2、R3、R4和R5如本处所定义。本文提供了聚(ADP核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物,以及使用本文描述的化合物或药物组合物治疗通过抑制PARP活性而改善的疾病、疾病和症状。
  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY
    申请人:Chu Daniel
    公开号:US20110190288A1
    公开(公告)日:2011-08-04
    A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    化合物具有以下公式(I)和公式(II)所示的结构: 其中,取代基Y、Z、A、B、R1、R2、R3、R4和R5的定义如本文所述。本文提供了聚(ADP-核糖)聚合酶活性抑制剂。本文还描述了包括至少一种本文所述化合物的制药组合物,以及使用本文所述的化合物或制药组合物治疗与PTEN缺陷相关的疾病、紊乱和病况,这些疾病、紊乱和病况通过抑制PARP活性得到改善。
  • [EN] DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) FOR THE TREATMENT OF MULTIPLE MYELOMA<br/>[FR] INHIBITEURS DIHYDROPYRIDOPHTHALAZINONE DE POLY (ADP-RIBOSE) POLYMÉRASE (PARP) POUR LE TRAITEMENT DU MYÉLOME MULTIPLE
    申请人:BIOMARIN PHARM INC
    公开号:WO2013028495A1
    公开(公告)日:2013-02-28
    Provided is a methods of treating multiple myeloma with inhibitors of poly(ADP-ribose)polymerase according to Formula (I):
    提供了一种使用聚(ADP-核糖)聚合酶抑制剂治疗多发性骨髓瘤的方法,该抑制剂化学式为(I)。
  • Polymeric Compound Having Camptothecin Compound And Anti-Cancer Effect Enhancer Bound Thereto, And Use of Same
    申请人:NIPPON KAYAKU KABUSHIKI KAISHA
    公开号:US20150290185A1
    公开(公告)日:2015-10-15
    The purpose of the present invention is to provide a polymeric compound in which a camptothecin compound and an anti-cancer effect enhancer, particularly a PARP inhibitor, are bound to a single molecule, whereby it becomes possible to reduce the toxicity to normal cells and deliver and release the two components to an affected area with high efficiency to thereby improve the pharmacological efficacy of the two components. Provided is a polymeric compound represented by general formula (1).
    本发明的目的是提供一种聚合物化合物,其中一种喜树碱化合物和一种抗癌效应增强剂,特别是PARP抑制剂,结合到单个分子中,从而可以降低对正常细胞的毒性,并以高效率将两个组分传递和释放到受影响的区域,从而提高两个组分的药理功效。提供了由通式(1)表示的聚合物化合物。
  • Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
    申请人:BioMarin Pharmaceutical Inc.
    公开号:US08012976B2
    公开(公告)日:2011-09-06
    A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.
    具有以下结构式(I)和结构式(II)的化合物:其中,取代基Y、Z、A、B、R1、R2、R3、R4和R5的定义如本文所述。本文提供了一种poly(ADP-核糖)聚合酶活性抑制剂。本文还描述了包括至少一种上述化合物的制药组合物,并使用上述化合物或制药组合物来治疗通过抑制PARP活性改善的疾病、疾病和病况。
查看更多